| Name | Title | Contact Details |
|---|---|---|
Jeff Leshuk |
Chief Revenue Officer | Profile |
Mike Rubidoux |
Director of Sales Strategy | Profile |
Delma Heileman |
Director, Retail Sales | Profile |
Michelle Mesina |
Vice President of People | Profile |
Michelle Mesina |
Vice President of People | Profile |
Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.
Ben Venue Laboratories is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal. Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed facility in Oak Ridge, Tenn.; a detritiation testing facility in Houston, Texas; two facilities in Richland, Wash., for non-radioactive demonstration testing, engineering and storage of mobile systems; and an office in Loveland, Colo. for engineering design and development.